Denali Therapeutics Inc DNLI:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 08/08/22 EDT
37.25quote price arrow up+37.25 (UNCH)
Volume
24,882
Close
37.25quote price arrow up+1.50 (+4.20%)
Volume
827,108
52 week range
20.24 - 56.80
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close37.25
  • 52 Week High56.80
  • 52 Week High Date09/02/21
  • 52 Week Low20.24
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap4.58B
  • Shares Out122.95M
  • 10 Day Average Volume0.59M
  • Dividend-
  • Dividend Yield-
  • Beta1.65
  • YTD % Change-16.48

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close37.25
  • 52 Week High56.80
  • 52 Week High Date09/02/21
  • 52 Week Low20.24
  • 52 Week Low Date05/12/22
  • Market Cap4.58B
  • Shares Out122.95M
  • 10 Day Average Volume0.59M
  • Dividend-
  • Dividend Yield-
  • Beta1.65
  • YTD % Change-16.48

RATIOS/PROFITABILITY

  • EPS (TTM)-2.34
  • P/E (TTM)-15.90
  • Fwd P/E (NTM)-12.92
  • EBITDA (TTM)-282.465M
  • ROE (TTM)-28.25%
  • Revenue (TTM)82.88M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-344.79%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date11/02/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Denali Therapeutics Inc

There is no recent news for this security.

Profile

MORE
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company clinical programs include leucine-rich repeat kinase 2 (LRRK2) inhibitor program, eukaryotic initiation factor 2 B (EIF2B) activator program, enzyme transport vehicle: iduronate 2-sulfatase...
Vicki Sato Ph.D.
Independent Chairman of the Board
Ryan Watts Ph.D.
President, Chief Executive Officer, Director
Alexander Schuth M.D.
Chief Financial Officer, Chief Operating Officer, Company Secretary
Address
161 Oyster Point Blvd
South San Francisco, CA
94080-1910
United States

Top Peers

SYMBOLLASTCHG%CHG
ZLAB
Zai Lab Ltd
47.08+1.81+4.00%
BEAM
Beam Therapeutics Inc
63.69+0.26+0.41%
CYTK
Cytokinetics Inc
53.54+1.72+3.32%
KRTX
Karuna Therapeutics Inc
241.19+100.83+71.84%
NTLA
Intellia Therapeutics Inc
63.49+0.17+0.27%